Table 2. Virologic Features of HVLPD... | American Society of Hematology

Table 2.

Virologic Features of HVLPD Patients

Patient	EBV type	Sites of EBV⁺ cells	EBV cell type	First EBV load (copies/mL)	EBV gene expression	EBV copies/10⁶ T/B/NK cells
1	1	Bone marrow EBV⁺, CSF⁺; skin EBV⁺ HVLPD	T cell	403 000	Negative for EBNA1, BZLF1	23 400 T/ 5356 B
2	ND	Skin HVLPD, EBV ND	T∼B cell	94 850	ND	249 T/ 451 B
3	1	Skin EBV⁺ HVLPD, bone marrow EBV⁺	T cell	4 510 000	Negative for EBNA1, BZLF1	350 638 T/ 12 148 B
4	1	skin HVLPD, EBV ND	T cell	583 500	Negative for EBNA1, BZLF1	486 661 T/ 6966 B
5	ND	Skin HVLPD, EBV ND; ileum EBV⁺ suggestive of T-cell LPD	T cell	196 500	ND	ND
6	1	Skin EBV⁺ HVLPD	T cell	728 500	Positive for EBNA1, BZLF1 (3+), Neg for LMP1, EBNA2	250 616 T/ 20 000 B
7	1	EBV⁺ HVLPD	T cell	250 150	Positive for EBNA1; Negative for EBNA2, LMP1, BZLF1	199 050 T/ 1761 B
8	ND	ND	T>NK	83 180*	ND	227 227 T/313 B/13 514 NK
9	1	ND	NK∼T	100 000*	ND	93 343 T/958 B/113 907 NK
10	1	ND	NK>T	245 500*	ND	43 005 T/857 B/245 979 NK
11	1	Skin T cell EBV⁺ HVLPD, EBV⁺ lymph node	T cell	320 000†	Positive for EBNA1, LMP1, BZLF1 (1+), Neg for EBNA2	ND
12	2	Skin HVLPD, EBV ND	T cell	840 350	Positive for EBNA1, BZLF1 (3+); Negative for LMP1, EBNA2	452 353 T/227 778 B
13	1	Skin, colon, pleura, muscle EBV⁺ HVLPD	B>T cell	1 514 800	Negative for EBNA1, BZLF1	2 022 000 T/18 410 000 B (EBV was predominantly in T cells in the tissues)
14	1	Skin (EBV⁺ HVLPD), liver, bone marrow, lymph node	T>NK cell	3 630 780*	Positive for EBNA1; Negative for BZLF1, EBNA2, LMP1	5 843 000 T/84 000 B/310 000 NK
15	1	Skin (EBV⁺ HVLPD), bone marrow, buccal and lingual mucosa,CSF with lymphocytic pleocytosis	T∼NK cell	1 659 586*	Positive for EBNA1; Negative for BZLF1, EBNA2, LMP1	1 633 000 T/20 000 B/1 513 000 NK
16	ND	Skin EBV⁺ HVLPD, lung and ileum EBV⁺ T cell lymphoma	T>NK cell	3 388 442*	ND	872 000 T/3672 B/660 000 NK

Patient	EBV type	Sites of EBV⁺ cells	EBV cell type	First EBV load (copies/mL)	EBV gene expression	EBV copies/10⁶ T/B/NK cells
1	1	Bone marrow EBV⁺, CSF⁺; skin EBV⁺ HVLPD	T cell	403 000	Negative for EBNA1, BZLF1	23 400 T/ 5356 B
2	ND	Skin HVLPD, EBV ND	T∼B cell	94 850	ND	249 T/ 451 B
3	1	Skin EBV⁺ HVLPD, bone marrow EBV⁺	T cell	4 510 000	Negative for EBNA1, BZLF1	350 638 T/ 12 148 B
4	1	skin HVLPD, EBV ND	T cell	583 500	Negative for EBNA1, BZLF1	486 661 T/ 6966 B
5	ND	Skin HVLPD, EBV ND; ileum EBV⁺ suggestive of T-cell LPD	T cell	196 500	ND	ND
6	1	Skin EBV⁺ HVLPD	T cell	728 500	Positive for EBNA1, BZLF1 (3+), Neg for LMP1, EBNA2	250 616 T/ 20 000 B
7	1	EBV⁺ HVLPD	T cell	250 150	Positive for EBNA1; Negative for EBNA2, LMP1, BZLF1	199 050 T/ 1761 B
8	ND	ND	T>NK	83 180*	ND	227 227 T/313 B/13 514 NK
9	1	ND	NK∼T	100 000*	ND	93 343 T/958 B/113 907 NK
10	1	ND	NK>T	245 500*	ND	43 005 T/857 B/245 979 NK
11	1	Skin T cell EBV⁺ HVLPD, EBV⁺ lymph node	T cell	320 000†	Positive for EBNA1, LMP1, BZLF1 (1+), Neg for EBNA2	ND
12	2	Skin HVLPD, EBV ND	T cell	840 350	Positive for EBNA1, BZLF1 (3+); Negative for LMP1, EBNA2	452 353 T/227 778 B
13	1	Skin, colon, pleura, muscle EBV⁺ HVLPD	B>T cell	1 514 800	Negative for EBNA1, BZLF1	2 022 000 T/18 410 000 B (EBV was predominantly in T cells in the tissues)
14	1	Skin (EBV⁺ HVLPD), liver, bone marrow, lymph node	T>NK cell	3 630 780*	Positive for EBNA1; Negative for BZLF1, EBNA2, LMP1	5 843 000 T/84 000 B/310 000 NK
15	1	Skin (EBV⁺ HVLPD), bone marrow, buccal and lingual mucosa,CSF with lymphocytic pleocytosis	T∼NK cell	1 659 586*	Positive for EBNA1; Negative for BZLF1, EBNA2, LMP1	1 633 000 T/20 000 B/1 513 000 NK
16	ND	Skin EBV⁺ HVLPD, lung and ileum EBV⁺ T cell lymphoma	T>NK cell	3 388 442*	ND	872 000 T/3672 B/660 000 NK

BZLF1 expression was graded 1+ to 4+.

CSF, cerebrospinal fluid; ND, not done.

IU/mL.

copies/10⁶ cells.